Nivagen focuses on developing, acquiring, and in-licensing unique formulations to build a broad portfolio of difficult-to-formulate generic and branded prescription drugs. The company serves the North American market and emphasizes rapid commercialization of new products. Management says it is expanding domestic manufacturing capability to ensure consistent supply and accelerate time to market. Nivagen intends to use new capital for internal development and acquisition of additional generic and branded drugs. The company also is exploring strategies to develop or acquire U.S. manufacturing facilities to help alleviate supply disruptions. Management highlighted medicines that help patients impacted by COVID-19 as part of its growing product pipeline.

Total raised

$16M

Funding rounds

1

Latest round

Equity

Latest activity

May 2020